SEM Q4 2025 Earnings Analysis
Listen On
Available In
Key Highlights
- Revenue and earnings analysis for Q4 2025
- Key financial metrics and performance indicators
- Management guidance and outlook commentary
- Market position and competitive analysis
- AI-generated insights and analysis
Transcript
// Full episode scriptBeta Finch Podcast Script
Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the corporate speak to give you the insights that matter. I'm Alex.
And I'm Jordan. Today we're diving into Select Medical's Q4 2025 earnings call - and folks, there's a lot to unpack here beyond just the numbers.
Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Absolutely. Now Alex, Select Medical had quite the quarter, but there's an elephant in the room we need to address first.
You're talking about the take-private proposal, right? CEO Tom Mullen opened the call by addressing this head-on. They received a non-binding indication of interest from their Executive Chairman back in November to acquire all outstanding shares.
That's creating some major strategic uncertainty. A special committee is evaluating the proposal, but they're staying tight-lipped about the process. When analysts pressed for more details about timing or other strategic alternatives, CFO Mike Malatesta essentially said "no comment."
Which makes sense from a legal standpoint, but it definitely adds complexity for investors trying to evaluate the business fundamentals. Speaking of which, let's dig into those numbers. Revenue grew over 6% year-over-year to hit about $1.3 billion in Q4, with all three divisions showing growth.
But here's where it gets interesting - while revenue was up, adjusted EBITDA actually fell 10% to $104.7 million. That's a pretty significant disconnect, and it really came down to two main culprits.
Right, and this is where the outpatient rehab division really struggled. They saw their EBITDA margin crash from 8.3% last year to just 3.4% this quarter. Jordan, can you break down what went wrong there?
It's actually a perfect storm of issues. First, they got hit with about $5 million in unexpected health insurance costs - apparently they saw higher-cost claimants and increased utilization across their benefits. But the bigger issue was $6 million in what they called "variable discount write-offs."
That's corporate speak for "we had to write off some old receivables we couldn't collect," right?
Exactly. CFO Malatesta explained these were receivables spanning about two years that they finally gave up on after exhausting collection efforts. On top of that, they're dealing with an unfavorable payer mix shift - more managed Medicare, less workers' comp.
But here's what caught my attention - CEO Mullen mentioned they're expecting a 2% Medicare rate increase in 2026. He called it "the first time in many years." That could be a meaningful tailwind for the outpatient business.
Definitely. And management seemed confident that the $11 million hit from health costs and write-offs were "truly one-timers." They're expecting outpatient margins to improve year-over-year in 2026, though they're being cautiously optimistic.
Now let's talk about their growth engine - the inpatient rehabilitation division. This is where Select Medical is really firing on all cylinders.
Revenue jumped over 15% year-over-year to $339 million, and they added 150 beds in Q4 alone through new hospital openings and acquisitions. They're working with some big-name health systems like Cleveland Clinic and Baylor Scott & White.
The pipeline looks robust too. They're expecting to add 399 beds across 2026 and 2027, with some already opening in January. This division is clearly their main growth driver, with occupancy at 82% and same-store occupancy even higher at 86%.
What I found interesting in the Q&A was when an analyst asked about startup losses in the IRF division. Malatesta said same-store margins were still over 23%, but startup costs are dragging down the overall division margin to about 20%. They're expecting around $15 million in startup losses for 2026.
The critical illness recovery division was the steady performer - revenue up nearly 5%, EBITDA up 5%, margins holding steady at 10.5%. Nothing flashy, but consistent.
Let's talk balance sheet quickly. They ended with $1.8 billion in debt and just $26.5 million in cash. Net leverage hit 3.67x, which is getting up there, though they do have substantial revolver capacity available.
For 2026 guidance, they're projecting revenue of $5.6 to $5.8 billion - that's solid growth. Adjusted EBITDA is expected between $520 to $540 million, which would be an improvement from this year's $493 million.
The earnings per share guidance of $1.22 to $1.32 suggests they expect meaningful improvement from this year's $1.16. But remember, all of this assumes business as usual while that take-private evaluation is happening.
One thing that struck me from the call was how management handled questions about capital allocation. When asked about share repurchases, Malatesta was direct: the take-private review "puts everything on hold."
That's probably the right approach, but it does create uncertainty. Interestingly, they're continuing with their expansion plans - it's "business as usual" on the operational front while the strategic review continues.
Before we wrap up, there were a couple of interesting tidbits. They're piloting AI initiatives for back-office billing processes and outpatient collections. They're also looking at clinical applications like virtual sitters and telemetry monitoring.
And labor costs seem to have stabilized after the chaos of 2021-2023. Their agency mix is running around 15%, which is their target, and labor margins are just above 56%.
So what's the bottom line for investors? Select Medical has a solid growth story in inpatient rehab, but the outpatient headwinds are real. The take-private proposal adds a wild card that could trump all fundamental analysis.
I think the key is watching whether they can execute on that robust IRF pipeline while fixing the outpatient issues. The Medicare rate increase should help, but they need to prove they can improve those margins. And of course, we'll all be watching what happens with the take-private process.
The guidance suggests management is confident in a turnaround, but with net leverage at 3.67x and limited cash, they don't have much room for error.
Before we sign off, I want to remind our listeners that everything we've discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
That's a wrap on this episode of Beta Finch. We'll be back next time with another earnings breakdown. Until then, keep those portfolios diversified and those expectations realistic.
See you next time! ---